Advertisement

PharmacoEconomics & Outcomes News

, Volume 797, Issue 1, pp 13–13 | Cite as

Daclatasvir/asunaprevir worth its cost for chronic HCV genotype 1b

Clinical study
  • 7 Downloads

Reference

  1. Liu Y, et al. Cost Effectiveness of Daclatasvir Plus Asunaprevir Therapy for Chinese Patients with Chronic Hepatitis C Virus Genotype 1b. Clinical Drug Investigation : 7 Feb 2018. Available from: URL: http://doi.org/10.1007/s40261-018-0621-9

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Personalised recommendations